Non-Current Assets
PP&E (Net)
Neurocrine Biosciences PP&E (Net) increased by 1.2% to $90.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.5%, from $87.00M to $90.90M. Over 5 years (FY 2020 to FY 2025), PP&E (Net) shows an upward trend with a 15.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates ongoing investment in physical capacity, whereas a decline may suggest aging assets or a strategy of asset-light operations.
Detailed definition
This metric represents the book value of tangible assets after subtracting accumulated depreciation from the total histo...
Peer comparison
Standard line item for all manufacturing and industrial companies; directly comparable across peers.
Metric ID:
property_plant_equipment_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $50.00M | $51.10M | $58.60M | $63.90M | $66.80M | $60.90M | $58.60M | $62.80M | $65.60M | $68.80M | $70.80M | $75.30M | $80.10M | $80.00M | $82.60M | $87.00M | $91.70M | $97.30M | $89.80M | $90.90M |
| QoQ Change | — | +2.2% | +14.7% | +9.0% | +4.5% | -8.8% | -3.8% | +7.2% | +4.5% | +4.9% | +2.9% | +6.4% | +6.4% | -0.1% | +3.3% | +5.3% | +5.4% | +6.1% | -7.7% | +1.2% |
| YoY Change | — | — | — | — | +33.6% | +19.2% | +0.0% | -1.7% | -1.8% | +13.0% | +20.8% | +19.9% | +22.1% | +16.3% | +16.7% | +15.5% | +14.5% | +21.6% | +8.7% | +4.5% |
Range$50.00M – $97.30M
CAGR+13.4%
Avg YoY Growth+13.9%
Median YoY Growth+15.9%
PP&E (Net) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's pp&e (net)?
- Neurocrine Biosciences (NBIX) reported pp&e (net) of $90.90M in Q1 2026.
- How has Neurocrine Biosciences's pp&e (net) changed year-over-year?
- Neurocrine Biosciences's pp&e (net) increased by 4.5% year-over-year, from $87.00M to $90.90M.
- What is the long-term trend for Neurocrine Biosciences's pp&e (net)?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's pp&e (net) has grown at a 15.0% compound annual growth rate (CAGR), from $44.60M to $89.80M.
- What does pp&e (net) mean?
- The current book value of physical assets after accounting for wear and tear.